MX2017005255A - Derivados de carbazol. - Google Patents

Derivados de carbazol.

Info

Publication number
MX2017005255A
MX2017005255A MX2017005255A MX2017005255A MX2017005255A MX 2017005255 A MX2017005255 A MX 2017005255A MX 2017005255 A MX2017005255 A MX 2017005255A MX 2017005255 A MX2017005255 A MX 2017005255A MX 2017005255 A MX2017005255 A MX 2017005255A
Authority
MX
Mexico
Prior art keywords
compounds
carbazole derivatives
formula
diseases
btk
Prior art date
Application number
MX2017005255A
Other languages
English (en)
Other versions
MX374724B (es
Inventor
Liu Qingjie
Hunter Watterson Scott
Ahmad Saleem
E Macor John
Kumar Maishal Tarun
A Tino Joseph
Kesavan Nair Satheesh
G Batt Douglas
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005255(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2017005255A publication Critical patent/MX2017005255A/es
Publication of MX374724B publication Critical patent/MX374724B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen los compuestos de la fórmula (I): (ver Fórmula) o una de sus sales, en donde: Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, y R7d se definen en la presente. También se describen métodos de uso de tales compuestos como inhibidores de la tirosina cinasa de Bruton (Btk) y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son de utilidad en el tratamiento, prevención o lentificación de la progresión de enfermedades o trastornos en una variedad de áreas terapéuticas, tales como enfermedades autoinmunes y enfermedad vascular.
MX2017005255A 2014-10-24 2015-10-23 Derivados de carbazol. MX374724B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24
PCT/US2015/057077 WO2016065236A1 (en) 2014-10-24 2015-10-23 Carbazole derivatives

Publications (2)

Publication Number Publication Date
MX2017005255A true MX2017005255A (es) 2017-08-18
MX374724B MX374724B (es) 2025-03-06

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005255A MX374724B (es) 2014-10-24 2015-10-23 Derivados de carbazol.

Country Status (34)

Country Link
US (3) US10266491B2 (es)
EP (1) EP3209651B9 (es)
JP (1) JP6599983B2 (es)
KR (1) KR102514914B1 (es)
CN (1) CN107074804B (es)
AR (1) AR102427A1 (es)
AU (1) AU2015335703B2 (es)
BR (1) BR112017007545A2 (es)
CA (1) CA2965523A1 (es)
CL (1) CL2017001001A1 (es)
CO (1) CO2017004517A2 (es)
CY (1) CY1122549T1 (es)
DK (1) DK3209651T3 (es)
EA (1) EA032361B1 (es)
ES (1) ES2761903T3 (es)
HR (1) HRP20192197T2 (es)
HU (1) HUE048321T2 (es)
IL (1) IL251798B (es)
LT (1) LT3209651T (es)
MA (1) MA40302B1 (es)
ME (1) ME03754B (es)
MX (1) MX374724B (es)
MY (1) MY190568A (es)
PE (1) PE20171239A1 (es)
PH (1) PH12017500724B1 (es)
PL (1) PL3209651T3 (es)
PT (1) PT3209651T (es)
RS (1) RS59707B1 (es)
SG (2) SG11201703187PA (es)
SI (1) SI3209651T1 (es)
SM (1) SMT202000035T1 (es)
TN (1) TN2017000158A1 (es)
TW (1) TWI676618B (es)
WO (1) WO2016065236A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6592512B2 (ja) * 2014-10-24 2019-10-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式アトロプ異性体の化合物
AU2015336480B2 (en) 2014-10-24 2020-04-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN109153680B (zh) * 2016-07-07 2021-04-23 株式会社大熊制药 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
CN114829350B (zh) * 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法
AU2021253584A1 (en) * 2020-04-10 2022-11-17 Gb005, Inc. Kinase inhibitors
CN115867346B (zh) * 2020-06-02 2025-03-14 Gb005股份有限公司 激酶抑制剂
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺
IL317988A (en) * 2022-07-06 2025-02-01 Vividion Therapeutics Inc Pharmaceutical preparations comprising helix inhibitors of
CR20250159A (es) * 2022-09-29 2025-07-04 Vividion Therapeutics Inc Derivados de n–acriloilmorfolina como moduladores de keap1 y sus usos
WO2026067706A1 (zh) * 2024-09-30 2026-04-02 杭州邦顺制药有限公司 Keap1调节剂

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
CA2587192A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
AP2334A (en) 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8518964B2 (en) 2005-11-22 2013-08-27 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
AU2007297221B2 (en) 2006-09-11 2012-11-08 Mylan Laboratories Limited Dibenzofuran derivatives as inhibitors of PDE-4 and PDE-10
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
JP5487214B2 (ja) 2008-12-19 2014-05-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
EP2415184B1 (en) 2009-02-13 2019-04-10 Nextivity, Inc. Remote control for booster
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
WO2012066442A1 (en) 2010-11-15 2012-05-24 Pfizer Limited Inhibitors of hiv replication
CN103582637B (zh) 2011-05-17 2015-08-12 弗·哈夫曼-拉罗切有限公司 酪氨酸激酶抑制剂
CN104582705A (zh) 2012-01-10 2015-04-29 林伯士艾瑞斯公司 白介素-1受体相关激酶(irak)抑制剂和其用途
MX2015002975A (es) 2012-10-26 2015-06-22 Hoffmann La Roche Inhibidores de la tirosina cinasa de bruton.
WO2014210087A1 (en) * 2013-06-25 2014-12-31 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
TWI648272B (zh) * 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
JP6592512B2 (ja) * 2014-10-24 2019-10-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式アトロプ異性体の化合物
EA034931B1 (ru) 2014-10-24 2020-04-08 Бристол-Майерс Сквибб Компани Индолкарбоксамидные соединения

Also Published As

Publication number Publication date
EP3209651B9 (en) 2020-05-20
IL251798B (en) 2020-08-31
US20170362176A1 (en) 2017-12-21
AU2015335703A1 (en) 2017-06-08
AR102427A1 (es) 2017-03-01
CO2017004517A2 (es) 2017-08-31
MA40302A1 (fr) 2018-05-31
CL2017001001A1 (es) 2017-11-24
DK3209651T3 (da) 2020-02-03
HRP20192197T2 (hr) 2020-11-13
HRP20192197T8 (hr) 2020-04-03
SI3209651T1 (sl) 2019-12-31
PH12017500724B1 (en) 2023-07-05
AU2015335703B2 (en) 2020-05-21
PL3209651T3 (pl) 2020-03-31
EP3209651A1 (en) 2017-08-30
SMT202000035T1 (it) 2020-03-13
RS59707B1 (sr) 2020-01-31
EP3209651B1 (en) 2019-10-23
US20200255377A1 (en) 2020-08-13
CY1122549T1 (el) 2021-01-27
JP6599983B2 (ja) 2019-10-30
US10676434B2 (en) 2020-06-09
HRP20192197T1 (hr) 2020-03-06
EA201790745A1 (ru) 2017-08-31
CN107074804B (zh) 2020-02-18
PH12017500724A1 (en) 2017-10-09
MA40302B1 (fr) 2018-10-31
KR102514914B1 (ko) 2023-03-27
SG10201903619YA (en) 2019-05-30
US10266491B2 (en) 2019-04-23
US11053197B2 (en) 2021-07-06
CN107074804A (zh) 2017-08-18
IL251798A0 (en) 2017-06-29
MY190568A (en) 2022-04-27
JP2017535536A (ja) 2017-11-30
WO2016065236A1 (en) 2016-04-28
HUE048321T2 (hu) 2020-07-28
BR112017007545A2 (pt) 2017-12-19
PT3209651T (pt) 2019-12-30
CA2965523A1 (en) 2016-04-28
KR20170075756A (ko) 2017-07-03
TWI676618B (zh) 2019-11-11
ME03754B (me) 2021-04-20
TN2017000158A1 (en) 2018-10-19
ES2761903T3 (es) 2020-05-21
EA032361B1 (ru) 2019-05-31
MX374724B (es) 2025-03-06
US20190225583A1 (en) 2019-07-25
PE20171239A1 (es) 2017-08-24
LT3209651T (lt) 2020-01-10
TW201629014A (zh) 2016-08-16
SG11201703187PA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
MX2017005255A (es) Derivados de carbazol.
CL2017000992A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasa
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX2022002976A (es) Inhibidores selectivos de jak1.
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
UY35369A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
MX387097B (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
MX2016011468A (es) Inhibidores de calicreína plasmática humana.
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
MX2018004664A (es) Antagonistas de ep4.
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
CO2017005732A2 (es) Compuestos de dihidropirimidin-2-ona y sus usos médicos
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
ECSP18056196A (es) Derivados de indano
MX2019000159A (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa.

Legal Events

Date Code Title Description
FG Grant or registration